RT @OncBrothers@twitter.com
Day 3 #GI23 Highlights #CommunityOncology
1. #MOUNTAINEER: Tucat+Trast approved CRC
2. #SUNLIGHT: TAS102+Bev confirmed late option CRC
3. #E2211: Cape+Tem in pNET manuscript
4. #ctDNA kinetics CRC
5. TNT state in RectalCA
@ASCO@twitter.com #OncEd #MedEd @OncoAlert@twitter.com #GISM #MedTwitter
🐦🔗: https://twitter.com/OncBrothers/status/1616940781562134534
#gi23 #communityoncology #mountaineer #sunlight #e2211 #ctDNA #OncEd #MedEd #gism #medtwitter
RT @OncBrothers@twitter.com
Day 1 #GI23 Highlights #CommunityOncology
1. #NeoAGIS: Chemo vs CROSS
2. #Infinity: NeoAdj IO dMMR G/GEJ Ca
3. #SPOTLIGHT: CLDN18.2 (Importance of NGS)- New SoC
4. #INTEGRATEIIA: Rego in pretreated pts
@ASCO@twitter.com #OncEd #MedEd #Oncology @OncoAlert@twitter.com @HemOncFellows@twitter.com #gism
🐦🔗: https://twitter.com/OncBrothers/status/1616211370411970561
#gi23 #communityoncology #neoagis #infinity #Spotlight #integrateiia #OncEd #MedEd #oncology #gism